Lisanti Capital Growth LLC Decreases Stock Holdings in ANI Pharmaceuticals, Inc. $ANIP

Lisanti Capital Growth LLC lowered its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 9.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 95,165 shares of the specialty pharmaceutical company’s stock after selling 10,260 shares during the quarter. ANI Pharmaceuticals accounts for 1.7% of Lisanti Capital Growth LLC’s portfolio, making the stock its 12th largest position. Lisanti Capital Growth LLC owned about 0.44% of ANI Pharmaceuticals worth $6,210,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in ANIP. Advisors Asset Management Inc. bought a new position in shares of ANI Pharmaceuticals during the 1st quarter valued at $28,000. Caitong International Asset Management Co. Ltd lifted its holdings in ANI Pharmaceuticals by 4,636.4% in the second quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company’s stock valued at $34,000 after acquiring an additional 510 shares during the period. National Bank of Canada FI purchased a new position in ANI Pharmaceuticals in the first quarter worth about $79,000. Emerald Advisers LLC grew its stake in shares of ANI Pharmaceuticals by 414.8% during the 2nd quarter. Emerald Advisers LLC now owns 1,256 shares of the specialty pharmaceutical company’s stock valued at $82,000 after purchasing an additional 1,012 shares during the period. Finally, Mesirow Financial Investment Management Inc. bought a new stake in shares of ANI Pharmaceuticals during the 1st quarter valued at about $206,000. Institutional investors own 76.05% of the company’s stock.

Analyst Ratings Changes

ANIP has been the topic of a number of research reports. Zacks Research raised shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 21st. HC Wainwright boosted their price objective on shares of ANI Pharmaceuticals from $93.00 to $121.00 and gave the company a “buy” rating in a research report on Wednesday, September 17th. Truist Financial upped their price objective on ANI Pharmaceuticals from $77.00 to $90.00 and gave the stock a “hold” rating in a research note on Thursday, October 9th. Guggenheim raised their target price on ANI Pharmaceuticals from $86.00 to $114.00 and gave the stock a “buy” rating in a report on Monday, September 8th. Finally, JPMorgan Chase & Co. lifted their target price on ANI Pharmaceuticals from $95.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, September 24th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $99.14.

ANI Pharmaceuticals Trading Up 0.2%

ANIP stock opened at $90.43 on Friday. The company has a market capitalization of $1.96 billion, a price-to-earnings ratio of -117.44 and a beta of 0.54. The business has a 50 day simple moving average of $93.58 and a two-hundred day simple moving average of $77.60. ANI Pharmaceuticals, Inc. has a 1-year low of $52.50 and a 1-year high of $99.50. The company has a debt-to-equity ratio of 1.39, a current ratio of 2.54 and a quick ratio of 1.96.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.74 by $0.30. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The company had revenue of $227.81 million for the quarter, compared to the consensus estimate of $211.92 million. During the same period in the previous year, the firm posted $1.34 EPS. ANI Pharmaceuticals’s revenue for the quarter was up 53.6% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. Research analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

Insider Activity

In related news, SVP Chad Gassert sold 20,000 shares of the firm’s stock in a transaction on Friday, August 15th. The shares were sold at an average price of $86.97, for a total value of $1,739,400.00. Following the completion of the transaction, the senior vice president directly owned 173,226 shares of the company’s stock, valued at approximately $15,065,465.22. This trade represents a 10.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Muthusamy Shanmugam sold 52,990 shares of the company’s stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $87.15, for a total transaction of $4,618,078.50. Following the sale, the chief operating officer owned 531,920 shares in the company, valued at $46,356,828. This represents a 9.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 413,830 shares of company stock worth $36,505,378. 11.10% of the stock is owned by corporate insiders.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.